Table 2. Case Series of BRCA Mutations in Prostate Cancer
| Study | Population | Prostate Cancer Risk (BRCA1) | Prostate Cancer Risk (BRCA2) |
| BCLC, 1999 [3] | BCLC family set that included 173 BRCA2 linkage or mutation-positive families, among which there were 3,728 individuals and 333 cancersa | Not assessed | Overall: RR, 4.65 (95% CI, 3.48–6.22) |
| Men <65 y: RR, 7.33 (95% CI, 4.66–11.52) | |||
| Thompson et al., 2001 [4] | BCLC family set that included 164 BRCA2 mutation-positive families, among which there were 3,728 individuals and 333 cancersa | Not assessed | OCCR: RR, 0.52 (95% CI, 0.24–1.00) |
| Thompson et al., 2002 [1] | BCLC family set that included 7,106 women and 4,741 men, among which 2,245 were BRCA1 mutation carriers, 1,106 were tested noncarriers, and 8,496 were not tested for mutations | Overall: RR, 1.07 (95% CI, 0.75–1.54) | Not assessed |
| Men <65 y: RR, 1.82 (95% CI, 1.01–3.29) |
| BCLC = Breast Cancer Linkage Consortium; CI = confidence interval; OCCR = Ovarian Cancer Cluster Region; RR = relative risk. | |||
| aIncludes all cancers except breast, ovarian, and nonmelanoma skin cancers. |
References
- Thompson D, Easton DF; Breast Cancer Linkage Consortium.: Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94 (18): 1358-65, 2002. [PUBMED Abstract]
- Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 91 (15): 1310-6, 1999. [PUBMED Abstract]
- Thompson D, Easton D; Breast Cancer Linkage Consortium.: Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 68 (2): 410-9, 2001. [PUBMED Abstract]
